<!DOCTYPE html>
<html lang="en">

<head>
  <meta charset="utf-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1">

  <title>Conditioned place preference studies with atomoxetine in an animal model of ADHD effects of previous atomoxetine treatment</title>
  <meta name="description" content="To investigate the putative rewarding effects of atomoxetine, a non-stimulant medication for Attention-deficit/hyperactivity disorder (ADHD), we conducted co...">

  <link rel="stylesheet" href="/assets/main.css">

  <link rel="stylesheet" href="/assets/animate.css">

  <link rel="stylesheet" href="/assets/icomoon.css">

  <link rel="stylesheet" href="/assets/bootstrap.css">

  <link rel="stylesheet" href="/assets/superfish.css">

  <link href='https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,300' rel='stylesheet' type='text/css'>

  <link rel="stylesheet" href="/assets/style.css">

  <link rel="stylesheet" href="/assets/custom.css">

  <!-- Place favicon.ico and apple-touch-icon.png in the root directory -->
<!--  <link rel="shortcut icon" href="favicon.ico">-->

  <link href='https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,300' rel='stylesheet' type='text/css'>



  <link rel="canonical" href="http://localhost:4000/trineurotec/2011/09/30/Conditioned-place-preference-studies.html">


  <link rel="alternate" type="application/rss+xml" title="Trineurotec" href="/feed.xml">


  
</head>

  <body>


    <div id="fh5co-wrapper">

<div id="fh5co-page">

  <nav class="navbar navbar--size--md navbar--color--white">
    <div class="container">
      <h1 class="navbar-text"><a href="../../../../../index.html">Tri<span style="color:#FCC72C">neuro</span>tec</a></h1>
      <div class="collapse navbar-collapse" id="mobileNav" style="margin-top: 11px;">
        <ul class="sf-menu" id="fh5co-primary-menu">
          <li>
            <a id="homeNav" href="../../../../../index.html">Home</a>
          </li>
          <li><a id="aboutNav" href="../../../../../about.html" >About</a></li>
          <li><a id="whatNav" href="../../../../../what.html" >What we do</a></li>
          <li><a id="productsNav" href="../../../../../products.html" >Products</a></li>
          <li class="active"><a id="researchNav" href="../../../../../research.html" >Research</a></li>
          <li><a id="contactNav" href="../../../../../contact.html" >Contact</a></li>
        </ul>
      </div>
    </div>
  </nav>

  <div class="section" style="padding:70px 100px; font-family: "游ゴシック", YuGothic, "ヒラギノ角ゴ Pro", "Hiragino Kaku Gothic Pro", "メイリオ", "Meiryo", sans-serif;">
    <div class="container-research">
      <div class="post">

        <h3 class="post-title" style="font-size: 30px; font-weight: 300; line-height: 40px;">Conditioned place preference studies with atomoxetine in an animal model of ADHD effects of previous atomoxetine treatment</h3>
        <div class="post-info">
          <span>&nbsp;</span>dela Peña IC, Ahn HS, Ryu JH, Shin CY, Park IH, Cheong JH

        </div>
        <br>
        <br>
        <div class="post-line"></div>

        <p>To investigate the putative rewarding effects of atomoxetine, a non-stimulant medication for Attention-deficit/hyperactivity disorder (ADHD), we conducted conditioned place preference (CPP) tests in an animal model of ADHD, the spontaneously hypertensive rat (SHR). The effects of drug pre-exposure were also evaluated, thus, parallel experiments were done in rats which have undergone 14 days of atomoxetine treatment. The responses of SHR were compared with the rat strain representing the “normal” heterogeneous population, the Wistar rats. Neither rat strain showed significant CPP to atomoxetine. However, previous atomoxetine treatment produced place preference responses in rats, more profoundly in Wistar rats conditioned with the low and moderate atomoxetine doses. In conclusion, acute exposure to atomoxetine does not have any rewarding effect, however, drug pretreatment produces responses characteristic of reward or psychological dependence, more specifically in the “normal” vs. the ADHD animal model. The present findings call for more studies with atomoxetine, especially those that investigate the effects of long-term or chronic drug treatment.</p>


      </div>
    </div>
  </div>




</div>

</div>



    <footer class="site-footer">

  <div class="wrapper-footer">

    <h2 class="footer-heading">Trineurotec</h2>

    <div class="footer-col-wrapper">
      <div class="footer-col footer-col-1">
        <ul class="contact-list">
          <li>
            
              Trineurotec
            
            </li>
            
        </ul>
      </div>

      <div class="footer-col footer-col-2">
        <ul class="social-media-list">
        <!--  
          <li>
            <a href="https://github.com/trineurotec"><span class="icon icon--github"><svg viewBox="0 0 16 16" width="16px" height="16px"><path fill="#828282" d="M7.999,0.431c-4.285,0-7.76,3.474-7.76,7.761 c0,3.428,2.223,6.337,5.307,7.363c0.388,0.071,0.53-0.168,0.53-0.374c0-0.184-0.007-0.672-0.01-1.32 c-2.159,0.469-2.614-1.04-2.614-1.04c-0.353-0.896-0.862-1.135-0.862-1.135c-0.705-0.481,0.053-0.472,0.053-0.472 c0.779,0.055,1.189,0.8,1.189,0.8c0.692,1.186,1.816,0.843,2.258,0.645c0.071-0.502,0.271-0.843,0.493-1.037 C4.86,11.425,3.049,10.76,3.049,7.786c0-0.847,0.302-1.54,0.799-2.082C3.768,5.507,3.501,4.718,3.924,3.65 c0,0,0.652-0.209,2.134,0.796C6.677,4.273,7.34,4.187,8,4.184c0.659,0.003,1.323,0.089,1.943,0.261 c1.482-1.004,2.132-0.796,2.132-0.796c0.423,1.068,0.157,1.857,0.077,2.054c0.497,0.542,0.798,1.235,0.798,2.082 c0,2.981-1.814,3.637-3.543,3.829c0.279,0.24,0.527,0.713,0.527,1.437c0,1.037-0.01,1.874-0.01,2.129 c0,0.208,0.14,0.449,0.534,0.373c3.081-1.028,5.302-3.935,5.302-7.362C15.76,3.906,12.285,0.431,7.999,0.431z"/></svg>
</span><span class="username">trineurotec</span></a>

          </li>
          

          
          <li>
            <a href="https://twitter.com/trineurotec"><span class="icon icon--twitter"><svg viewBox="0 0 16 16" width="16px" height="16px"><path fill="#828282" d="M15.969,3.058c-0.586,0.26-1.217,0.436-1.878,0.515c0.675-0.405,1.194-1.045,1.438-1.809c-0.632,0.375-1.332,0.647-2.076,0.793c-0.596-0.636-1.446-1.033-2.387-1.033c-1.806,0-3.27,1.464-3.27,3.27 c0,0.256,0.029,0.506,0.085,0.745C5.163,5.404,2.753,4.102,1.14,2.124C0.859,2.607,0.698,3.168,0.698,3.767 c0,1.134,0.577,2.135,1.455,2.722C1.616,6.472,1.112,6.325,0.671,6.08c0,0.014,0,0.027,0,0.041c0,1.584,1.127,2.906,2.623,3.206 C3.02,9.402,2.731,9.442,2.433,9.442c-0.211,0-0.416-0.021-0.615-0.059c0.416,1.299,1.624,2.245,3.055,2.271 c-1.119,0.877-2.529,1.4-4.061,1.4c-0.264,0-0.524-0.015-0.78-0.046c1.447,0.928,3.166,1.469,5.013,1.469 c6.015,0,9.304-4.983,9.304-9.304c0-0.142-0.003-0.283-0.009-0.423C14.976,4.29,15.531,3.714,15.969,3.058z"/></svg>
</span><span class="username">trineurotec</span></a>

          </li>
          -->
        </ul>
      </div>

      <div class="footer-col footer-col-3">
        <p>No.1 drug development company for ADHD and other neurodevelopment disorders.
</p>
      </div>
    </div>

  </div>

</footer>



  </body>

</html>
